Children exposed to their mother’s cancer and cancer treatment did not appear to have cardiac, cognitive, or general developmental issues up to 36 months of age.
Some patients with early-stage HR-positive breast cancer can be treated with hormone therapy alone, avoiding chemo without increasing their recurrence risk.
A study showed that tumors of younger patients with early-onset colorectal cancer differ from the tumors of those diagnosed later in life, both genetically and epigenetically.
Nonfunctional neuroendocrine tumors of lung or gastrointestinal origin were safely and effectively treated with the mTOR inhibitor everolimus.
Patients with midgut neuroendocrine tumors had significantly delayed disease progression when treated with Lutathera compared with the current standard of care.
A genomic analysis of the primary tumors and brain metastases of patients has revealed potentially targetable mutations only present in the brain metastases.
Undergoing primary surgery may be the best treatment option for patients with advanced oropharyngeal and hypopharyngeal cancers.
Cabozantinib significantly delayed progression of disease compared with everolimus in patients with advanced clear cell renal cell carcinoma.
Data taken from EUROCARE showed large variations in survival rates from several hematologic malignancies across European countries, with lower survival in Eastern Europe and higher survival in Northern and Central Europe.
New research has shown that there are genetic factors that drive which breast cancers will relapse and metastasize and which will not, and the identification of these factors may help clinicians identify patients at higher risk for recurrence.